AI assistant
Oramed Pharmaceuticals Inc. — Director's Dealing 2026
Jan 5, 2026
6965_dirs_2026-01-05_963a5cd2-8dd5-4ad7-b5df-7c2e389e145c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2025-12-31
Reporting Person: Shapiro Benjamin (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Common Stock | A | 30000 | — | Acquired | 119720 | Direct |
| 2025-12-31 | Common Stock | A | 3500 | — | Acquired | 123220 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1900000 | Indirect |
Footnotes
F1: Represents Restricted Stock Units ("RSUs"). The RSUs will vest ratably in three annual tranches beginning January 1, 2027. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.
F2: Represents RSUs. The RSUs will vest in quarterly installments over a one-year period starting April 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
F3: These shares of Common Stock are held by a trust of which the reporting person is a trustee and beneficiary.